Ontology highlight
ABSTRACT:
SUBMITTER: Seymour JF
PROVIDER: S-EPMC4219463 | biostudies-literature | 2014 Aug
REPOSITORIES: biostudies-literature
Seymour J F JF Kim D W DW Rubin E E Haregewoin A A Clark J J Watson P P Hughes T T Dufva I I Jimenez J L JL Mahon F-X FX Rousselot P P Cortes J J Martinelli G G Papayannidis C C Nagler A A Giles F J FJ
Blood cancer journal 20140815
Aurora kinase overexpression has been observed in patients with hematologic malignancies. MK-0457, a pan-aurora kinase inhibitor that also inhibits the ABL T315I mutant, was evaluated to treat patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome (Ph+) acute lymphoblastic leukemia (ALL) with the T315I mutation. Adults with Ph+ chronic phase (CP)-, accelerated phase (AP)- or blast phase (BP)-CML, or ALL and documented BCR-ABL T315I mutation were treated with a 5-day continuo ...[more]